- Fellowship - UT Southwestern Medical Center (1999-2002), Hematology Oncology
- Residency - West Virginia University - Charleston Division (1997-1998), Internal Medicine
- Residency - Sanjay Gandhi (1989-1991), Immunology
- Residency - King George's Medical College, India (1984-1988), Internal Medicine
- Internship - King George's Medical College, India (1983-1984), Internal Medicine
- Medical School - King George's Medical College, India (1978-1983)
- Medical School - King George's Medical College, India (1984-1988), Internal Medicine
Udit Verma, M.D.
- Internal Medicine - Hematology/Oncology
- Colorectal Cancer
- Gallbladder/Bile Duct (Cholangiocarcinoma) Cancer
Udit Verma, M.D., D.M., came to UT Southwestern Medical Center in 1999 for his hematology/oncology fellowship. He continued on faculty after completing his fellowship in 2002.
A native of India, he completed medical school at one of the most prestigious medical schools in India, King George Medical School, Lucknow. He later completed postgraduate training in internal medicine, followed by a D.M. in clinical immunology at Sanjay Gandhi Post-Graduate Institute of Medical Sciences, Lucknow.
When he came to the United States in 1992, Dr. Verma worked as a research associate at Georgetown University in Washington, D.C. He did an internal medicine residency at the University of West Virginia-Charleston, and a hematology/oncology fellowship at UT Southwestern, where he currently serves on faculty.
Dr. Verma is board certified in internal medicine and hematology/oncology. He is a member of the American Society of Hematology and the American Society of Clinical Oncology.
Dr. Verma has a special interest in gastrointestinal malignancies, including colorectal, pancreatic, hepatobiliary, and gastric cancers, as well as neuroendocrine (carcinoid) and gastrointestinal stromal tumors (GIST).
He has been the lead researcher on studies published in many peer-reviewed journals, including Nature. His clinical research interests include finding novel therapies for gastrointestinal cancers.
Dr. Verma has taken an active role in the design and implementation of experimental multidisciplinary treatment protocols for gastrointestinal cancer at UT Southwestern.
He seeks to create a productive and friendly relationship with physicians who share a patient with him. He is available for clinical consultations, including second opinions, at any time.
Dr. Verma is an avid gardener and has grown award-winning produce. He likes photography, especially of nature. He has hiked Machu Picchu in Peru with his family. He has visited Kruger National Park in South Africa and driven through difficult terrain of the Swiss Alps with his wife.
He likes to spend time with his wife and two children. His wife is a physician and a colleague on faculty at UT Southwestern. His daughter is an M.D./Ph.D. student at UT Southwestern and his son graduated from Yale.
Meet Dr. Verma
Associate Professor of Internal Medicine in Hematology/Oncology
Cancer therapy has come a long way, but Udit Verma, M.D., D.M., believes it is nowhere near a point to be content with.
"My job as a physician is to help my patients get the best possible treatment. I consider them as partners in decision-making, provide them with good counsel, and then follow an appropriate management plan."
Dr. Verma specializes in gastrointestinal malignancies and treats patients with colorectal, pancreatic, liver, gall bladder, gastric, and bile duct cancers as well as neuroendocrine and gastrointestinal stromal cell tumors.
He is on the Gastrointestinal Cancers Disease Oriented Team at UT Southwestern Medical Center’s Simmons Cancer Center, and Associate Professor of Internal Medicine in Hematology/Oncology.
A cancer diagnosis can be devastating news to patients and those near and dear to them. Dr. Verma wants to make a positive impact in the lives of his patients, which is why he chose hematology/oncology as his area of expertise.
Dr. Verma believes that taking care of cancer patients requires astute clinical judgment and diligence, and this can make a large impact on outcome. Cancer care is rapidly evolving, and there is great potential for further research and improvement in the field.
Dr. Verma’s mission is to provide the best possible care to his patients to render them disease-free, and if that is not feasible, make them live longer and have a better quality of life. He treats his patients as partners in the decision-making process. He says that even in the most desperate situations, there is hope and he won’t stop fighting for them.
Dr. Verma came to UT Southwestern because of its reputation for excellent patient care, research, and medical education. Along with his colleagues at the GI oncology multidisciplinary clinic at Simmons Cancer Center, Dr. Verma provides the best possible care to his patients and carries out cutting-edge clinical research. He is sought often for a second opinion on highly complex cases.
Interleukin-2 activation of human bone marrow in long term cultures: an effective strategy for purging and generation of anti-tumor cytotoxic effectors.
Verma, UN, Bagg, A., Brown, E., Mazumder, A. Bone Marrow Transplant 1994 13 115
A syndrome of fibrosing pleuritis, pericarditis and synovitis with infantile contracture of fingers and toes in two sisters: Familial fibrosing serositis
Verma UN, Misra R, Radhakrisnan S, Maitra SC, Agarwal S, Singh RR J Rheumatology 1995 22 2349
A nucleosomal role of IKKalpha in histone H3 phosphorylation is critical for cytokine-induced activation of NF-kB regulated genes
Yamamoto Y, Verma UN, Prajapati S, and Gaynor RB Nature 2003 423 655
Enhanced Chemosensitivity to Irinotecan by RNA interference mediated down-regulation of the NF-B p65 subunit
Guo J, Verma UN, Gaynor RB, Frenkel EP, Beccera CR Clin Cancer Res 2004 10 3333
Protein phosphatase 2Cβ association with the IκB kinase complex is involved in regulating NF-κB activity
Prajapati, S., Verma, UN., Yamamoto, Y., Kwak, Y. T., and Gaynor, R. B J Biol Chem 2004 279 1739
Nuclear Role of I kappa B Kinase-gamma/NF-kappa B essential modulator (IKK gamma/NEMO) in NF-kappa B-dependent gene expression
Verma UN, Yamamoto Y, Prajapati and Gaynor RB J Biol Chem 2004 279 3509
The Varied Applications of Small Interference RNA
Verma UN, Becerra C Progress in Clinical Oncology 2005 2004 1-24
Small interfering RNAs directed against B-catenin inhibit the in vitro and in vivo growth of colon cancer cells.
Verma, UN, Surabhi, RM, Schmaltieg, A., Becerra, C and Gaynor, R. B. Clinical Cancer Research April 2003 9 1291-300
Sulindac enhances TNF-a mediated lung cancer cell apoptosis by inhibition of NF-kB.
Berman, K., Verma, UN, Harburg, G. Clinical Cancer Research February 2002 8 354-60
Ikappa B kinase alpha (IKKalpha ) regulates sub-cellular distribution and turnover of cyclin D1 by phosphorylation
Kwak YT, Li R, Becerra C, Tripathy D, Frenkel E, Verma UN J Biol Chem September 2005 280 33945-52
- Interleukin-2 activation of human bone marrow in long term cultures: an effective strategy for purging and generation of anti-tumor cytotoxic effectors.
- NF-kappaB Pathway
- Molecular Targets of Cancer Chemotherapy
- Exploring Role of siRNA Cancer Therapy
- Colorectal Cancer
- Gallbladder/Bile Duct (Cholangiocarcinoma) Cancer
- Liver Cancer
- Pancreatic Cancer
- Stomach/EG Junction Cancer
- Medical Treatment of Gastrointestinal Cancer
- Medical Treatment of Pancreatic Cancer
- Neuroendocrine Cancer
Q&A by Dr. Verma
Showing 1 locations